Skip to main content

Table 8 Results from the scenario analyses of PHiD-CV vaccination program vs. PCV13 in Taiwan

From: Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan

Parameter Base-case Scenario analysis Cost (millions) QALY ICER
Efficacy of PHiD-CV against 19A IPD 71% 19% −0.6 8 Dominant (cost saving)
Efficacy of PCV13 against ST3 IPD 0% 26% −6.6 21 Dominant (cost saving)
AOM inpatient IR reduced by 50% (2–9 years old) [per 100,000] 1 year: 1011.3; 2 year: 1026.1; 3 year: 826.2 4 year: 795.8; 5 year: 245.8 1 year: 505.7; 2 year: 513; 3 year: 413.1; 4 year: 397.9; 5 year: 122.9 −3.9 20 Dominant (cost saving)
% of AOM cases caused by S. pneumoniae vs. NTHi 35.9 (S. pneumoniae); 32.3 (NTHi) [55] 55.7 (S. pneumoniae); 22.9 (NTHi) [59] −0.8 6 Dominant (cost saving)
Efficacy against pneumonia PHiD-CV: 23.4% PHiD-CV: 23.4% −7.1 21 Dominant (cost saving)
PCV13: 23.7% PCV13: 23.4%
Efficacy of PCV13 against NTHi AOM reduced to −11% 0% −11% −14.4 38 Dominant (cost saving)
Efficacy of PHiD-CV against NTHi AOM reduced to 0 21.5% 0% 0.15 38 Dominated
Time horizon 10 years Life time −6.7 16 Dominant (cost saving)
Price of vaccines (for illustration only) Both priced at 1269.5 NTD/dose PHiD-CV reduced by 10% (1142.5 NTD/dose) −88.2 21 Dominant (cost saving)
  1. *base-case result: dominant/cost-saving (-6.7 million NTD with QALYs gain of 21)
  2. IR incidence rate, AOM acute otitis media, ICER incremental cost-effectiveness ratio, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal polysaccharide and NTHi protein D conjugate vaccine, NTD new Taiwan dollar, S. pneumoniae Streptococcus pneumoniae, ST serotype, VT vaccine type, QALY quality-adjusted life year, yr year
\